Form 4: Supernus Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition and disposal of company stock and restricted stock units on February 23, 2024.
Summary
- On February 23, 2024, Frank Mottola, SVP at Supernus Pharmaceuticals, reported transactions involving the company's common stock and restricted stock units (RSUs).
- Mottola acquired 1,875 shares of common stock at $0 and disposed of 937 shares at $29.06 to cover tax withholding requirements related to RSU vesting.
- He also disposed of 1,875 restricted stock units.
- Following these transactions, Mottola beneficially owns 7,249 shares of common stock and 5,625 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The restricted stock units vest in four equal annual installments, beginning on February 23, 2024.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates transactions by a key executive at Supernus Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of stock and RSU transactions. |
| 02/23/2024 | First vesting date for restricted stock units. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.